Eileen Maus

Chief Executive Officer

Eileen Maus brings 20 years as a healthcare industry sales and marketing executive with strategic planning experience to her role as Chief Executive Officer with Renovia.  Ms. Maus entered the women’s healthcare space during her 12 years with CYTYC Corporation, where she was a key contributor to Cytyc’s growth from $8 million to over $700 million, holding leadership roles from sales management to Vice President, Commercial Operations of the Surgical Division. Specifically, Ms. Maus built and managed sales forces for five new product launches, including the ThinPrep® Pap Test, ThinPrep® Imaging System, FirstCyte Breast Test, NovaSure Endometrial Ablation and Mammosite Targeted Radiation Treatment. In addition, Ms. Maus spearheaded the integration and commercialization of Cytyc’s surgical division.

Prior to Renovia, Ms. Maus served as Chief Commercial Officer of Constitutional Medical Investors, a portfolio company of Warburg Pincus. In addition to participating in the diligence of diagnostic companies for potential acquisition, she developed the commercial plan for a disruptive technology in the hematology space that was acquired by Roche Diagnostic.

Ms. Maus previously served as Chief Commercial Officer for Keystone Dental, where she created their marketing strategy to align with market needs, rebuilt their sales force and orchestrated the purchase of innovative products in a commoditized industry.

Ms. Maus is a graduate of LaSalle University, with a Bachelor of Science in Marketing and Communications.

Eileen Maus

Chief Executive Officer

Eileen Maus brings 20 years as a healthcare industry sales and marketing executive with strategic planning experience to her role as Chief Executive Officer with Renovia.  Ms. Maus entered the women’s healthcare space during her 12 years with CYTYC Corporation, where she was a key contributor to Cytec’s growth from $8 million to over $700 million, holding leadership roles from sales management to Vice President, Commercial Operations of the Surgical Division. Specifically, Ms. Maus built and managed sales forces for five new product launches, including the ThinPrep® Pap Test, ThinPrep® Imaging System, FirstCyte Breast Test, NovaSure Endometrial Ablation and Mammosite Targeted Radiation Treatment. In addition, Ms. Maus spearheaded the integration and commercialization of Cytyc’s surgical division.

Prior to Renovia, Ms. Maus served as Chief Commercial Officer of Constitutional Medical Investors, a portfolio company of Warburg Pincus. In addition to participating in the diligence of diagnostic companies for potential acquisition, she developed the commercial plan for a disruptive technology in the hematology space that was acquired by Roche Diagnostic.

Ms. Maus previously served as Chief Commercial Officer for Keystone Dental, where she created their marketing strategy to align with market needs, rebuilt their sales force and orchestrated the purchase of innovative products in a commoditized industry.

Ms. Maus is a graduate of LaSalle University, with a Bachelor of Science in Marketing and Communications.